Hostname: page-component-586b7cd67f-t8hqh Total loading time: 0 Render date: 2024-11-23T08:35:07.410Z Has data issue: false hasContentIssue false
  • English
  • Français

Parotid gland carcinoma: 32 years’ experience from a single institute

Published online by Cambridge University Press:  06 June 2019

T Nakano ,
R Yasumatsu ,
R Kogo ,
K Hashimoto ,
K Asai ,
S Ohga ,
H Yamamoto ,
T Nakashima  and
T Nakagawa
T Nakano*
Affiliation:
Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan Department of Head and Neck Surgery, National Kyushu Cancer Center, Fukuoka, Japan
R Yasumatsu
Affiliation:
Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
R Kogo
Affiliation:
Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
K Hashimoto
Affiliation:
Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
K Asai
Affiliation:
Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
S Ohga
Affiliation:
Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
H Yamamoto
Affiliation:
Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
T Nakashima
Affiliation:
Department of Otolaryngology, Kyushu Medical Center, Fukuoka, Japan
T Nakagawa
Affiliation:
Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
*
Author for correspondence: Dr Takafumi Nakano, Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Maidashi 3-3-1, Higashi-ku, Fukuoka 812-8582, Japan E-mail: [email protected] Fax: +81 92 642 5685
Get access Rights & Permissions [Opens in a new window]

Abstract

Background

Parotid gland carcinoma is a rare and complicated histopathological classification. Therefore, assembling a sufficient number of cases with long-term outcomes in a single institute can present a challenge.

Method

The medical records of 108 parotid gland carcinoma patients who were treated at Kyushu University Hospital, Fukuoka, Japan, between 1983 and 2014 were reviewed. The survival outcomes were analysed according to clinicopathological findings.

Results

Forty-six patients had low clinical stage tumours (I–II), and 62 patients had high clinical stage tumours (III–IV). Fifty-two, 10 and 46 patients had low-, intermediate- and high-grade tumours, respectively. Twenty-seven of 65 cases had positive surgical margins. In high clinical stage and intermediate- to high-grade tumours, adjuvant radiation therapy was correlated with local recurrence-free survival (p = 0.0244). Intermediate- to high-grade tumours and positive surgical margins were significantly associated with disease-specific survival in multivariate analysis (p = 0.0002 and p = 0.0058).

Conclusion

The results of this study show that adjuvant radiation therapy is useful for improved local control in patients with high clinical stage and intermediate- to high-grade tumours.

Keywords

Salivary Gland CancerPrognosesRadiotherapy, AdjuvantNeoplasm Recurrence, Local
Type
Main Articles
Information
The Journal of Laryngology & Otology , Volume 133 , Issue 7 , July 2019 , pp. 604 - 609
Copyright
Copyright © JLO (1984) Limited, 2019 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

Dr T Nakano takes responsibility for the integrity of the content of the paper

References

1Ettl, T, Schwarz-Furlan, S, Gosau, M, Reichert, TE. Salivary gland carcinomas. Oral Maxillofac Surg 2012;16:267–83Google Scholar
2Eveson, JW, Auclair, P, Gnepp, DR, El-Naggar, AK. Tumours of the salivary glands. In: Barnes, L, Eveson, JW, Reichart, P, Sidransky, D, eds. Pathology and Genetics of Head and Neck Tumours. World Health Organization Classification of Tumours, 3rd edn. Lyon: IARC Press, 2005;209–81Google Scholar
3Jouzdani, E, Yachouh, J, Costes, V, Faillie, JL, Cartier, C, Poizat, F et al. Prognostic value of a three-grade classification in primary epithelial parotid carcinoma: result of a histological review from a 20-year experience of total parotidectomy with neck dissection in a single institution. Eur J Cancer 2010;46:323–31Google Scholar
4Erovic, BM, Shah, MD, Bruch, G, Johnston, M, Kim, J, O'Sullivan, B et al. Outcome analysis of 215 patients with parotid gland tumors: a retrospective cohort analysis. J Otolaryngol Head Neck Surg 2015;44:43Google Scholar
5Chang, JW, Hong, HJ, Ban, MJ, Shin, YS, Kim, WS, Koh, YW et al. Prognostic factors and treatment outcomes of parotid gland cancer: a 10-year single-center experience. Otolaryngol Head Neck Surg 2015;153:981–9Google Scholar
6Godballe, C, Schultz, JH, Krogdahl, A, Møller-Grøntved, A, Johansen, J. Parotid carcinoma: impact of clinical factors on prognosis in a histologically revised series. Laryngoscope 2003;113:1411–17Google Scholar
7Pohar, S, Gay, H, Rosenbaum, P, Klish, D, Bogart, J, Sagerman, R et al. Malignant parotid tumors: presentation, clinical/pathologic prognostic factors, and treatment outcomes. Int J Radiat Oncol Biol Phys 2005;61:112–18Google Scholar
8Mendenhall, WM, Morris, CG, Amdur, RJ, Werning, JW, Villaret, DB. Radiotherapy alone or combined with surgery for salivary gland carcinoma. Cancer 2005;103:2544–50Google Scholar
9Terhaard, CH, Lubsen, H, Van der Tweel, I, Hilgers, FJ, Eijkenboom, WM, Marres, HA et al. Salivary gland carcinoma: independent prognostic factors for locoregional control, distant metastases, and overall survival: results of the Dutch head and neck oncology cooperative group. Head Neck 2004;26:681–92Google Scholar
10Cockerill, CC, Gross, BC, Contag, S, Rein, S, Moore, EJ, Olsen, KD et al. Pediatric malignant salivary gland tumors: 60 year follow up. Int J Pediatr Otorhinolaryngol 2016;88:1–6Google Scholar
11Mercante, G, Marchese, C, Giannarelli, D, Pellini, R, Cristalli, G, Manciocco, V et al. Oncological outcome and prognostic factors in malignant parotid tumours. J Craniomaxillofac Surg 2014;42:59–65Google Scholar
12Fu, KK, Leibel, SA, Levine, ML, Friedlander, ML, Boles, R, Phillips, TL. Carcinoma of the major and minor salivary glands: analysis of treatment results and sites and causes of failures. Cancer 1977;40:2882–90Google Scholar
13Laurie, SA, Licitra, L. Systemic therapy in the palliative management of advanced salivary gland cancers. J Clin Oncol 2006;24:2673–8Google Scholar
14Jeannon, JP, Calman, F, Gleeson, M, McGurk, M, Morgan, P, O'Connell, M et al. Management of advanced parotid cancer. A systematic review. Eur J Surg Oncol 2009;35:908–15Google Scholar
15Tullio, A, Marchetti, C, Sesenna, E, Brusati, R, Cocchi, R, Eusebi, V. Treatment of carcinoma of the parotid gland: the results of a multicenter study. J Oral Maxillofac Surg 2001;59:263–70Google Scholar
16Caballero, M, E Sosa, A, Tagliapietra, A, Grau, JJ. Metastatic adenoid cystic carcinoma of the salivary gland responding to cetuximab plus weekly paclitaxel after no response to weekly paclitaxel alone. Head Neck 2013;35:E52–410.1002/hed.21870Google Scholar
17Locati, LD, Bossi, P, Perrone, F, Potepan, P, Crippa, F, Mariani, L et al. Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study. Oral Oncol 2009;45:574–810.1016/j.oraloncology.2008.07.010Google Scholar
18Kadowaki, S, Yatabe, Y, Hirakawa, H, Komori, A, Kondoh, C, Hasegawa, Y et al. Complete response to trastuzumab-based chemotherapy in a patient with human epidermal growth factor receptor-2-positive metastatic salivary duct carcinoma ex pleomorphic adenoma. Case Rep Oncol 2013;6:450–5Google Scholar
19Limaye, SA, Posner, MR, Krane, JF, Fonfria, M, Lorch, JH, Dillon, DA et al. Trastuzumab for the treatment of salivary duct carcinoma. Oncologist 2013;18:294–300Google Scholar